Acute graft-versus-host disease
F Malard, E Holler, BM Sandmaier, H Huang… - Nature Reviews …, 2023 - nature.com
Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …
EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity
AC Lankester, MH Albert, C Booth… - Bone Marrow …, 2021 - nature.com
Inborn errors of immunity (IEI) are a group of rare heterogeneous diseases. Currently, more
than 400 monogenetic IEI have been identified and increasingly a genetic diagnosis can be …
than 400 monogenetic IEI have been identified and increasingly a genetic diagnosis can be …
[HTML][HTML] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical …
CL Kitko, J Pidala, HM Schoemans… - … and cellular therapy, 2021 - Elsevier
Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD)
that lead to severe manifestations remains a challenge. The standardization provided by the …
that lead to severe manifestations remains a challenge. The standardization provided by the …
Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation
Post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD)
prophylaxis, but it may cause dose-dependent toxicities, particularly in frail patients …
prophylaxis, but it may cause dose-dependent toxicities, particularly in frail patients …
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide
Allogeneic blood or marrow transplantation (BMT) physicians seek to optimize all possible
variables to improve outcomes. Selectable factors include conditioning, graft-versus-host …
variables to improve outcomes. Selectable factors include conditioning, graft-versus-host …
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond
Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …
Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies
In search of an ideal partner or alternative to conventional immunosuppressive agents,
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …
Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation
J Sugita, T Kamimura, T Ishikawa, S Ota, T Eto… - Bone marrow …, 2021 - nature.com
Abstract Posttransplant cyclophosphamide (PTCy: 100 mg/kg) has been increasingly used
in allogeneic hematopoietic stem cell transplantation, however, few studies compared …
in allogeneic hematopoietic stem cell transplantation, however, few studies compared …
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute …
Background There is no information on the impact of donor type in allogeneic hematopoietic
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …
Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation
SP Persaud, JK Ritchey, S Kim, S Lim… - The Journal of …, 2021 - Am Soc Clin Investig
Despite the curative potential of hematopoietic stem cell transplantation (HSCT),
conditioning-associated toxicities preclude broader clinical application. Antibody-drug …
conditioning-associated toxicities preclude broader clinical application. Antibody-drug …